This podcast features an interview with David Ricks, CEO of Eli Lilly, about the company's GLP-1 weight-loss drugs. The discussion covers the evolution of these drugs from an initially unexpected side effect to their current potential in treating various conditions, including obesity, cardiovascular disease, and potentially even Alzheimer's. Ricks explains the challenges of balancing ethical considerations of pricing with the high risks and investment involved in drug development, advocating for a value-based pricing model that considers the broader societal benefits. A key takeaway is that while AI is accelerating drug discovery, it's not a magic bullet, and significant hurdles remain in scaling access to these life-changing medications. The interview concludes with a discussion of the slower adoption of new technologies in Europe compared to the US.
